Andreas H. Scheel

4.0k total citations
60 papers, 1.6k citations indexed

About

Andreas H. Scheel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Andreas H. Scheel has authored 60 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Andreas H. Scheel's work include Lung Cancer Treatments and Mutations (14 papers), Cancer Genomics and Diagnostics (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Andreas H. Scheel is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Cancer Genomics and Diagnostics (11 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Andreas H. Scheel collaborates with scholars based in Germany, United Kingdom and United States. Andreas H. Scheel's co-authors include Reinhard Buettner, Jürgen Wolf, Anne M. Schultheis, Matthias Dobbelstein, Josef Rüschoff, Julie George, Thomas Zander, Hans‐Ulrich Schildhaus, Rieke Fischer and Roman K. Thomas and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Andreas H. Scheel

54 papers receiving 1.6k citations

Peers

Countries citing papers authored by Andreas H. Scheel

Since Specialization

Citations

This map shows the geographic impact of Andreas H. Scheel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas H. Scheel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas H. Scheel more than expected).

Fields of papers citing papers by Andreas H. Scheel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas H. Scheel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas H. Scheel. The network helps show where Andreas H. Scheel may publish in the future.

Co-authorship network of co-authors of Andreas H. Scheel

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas H. Scheel. A scholar is included among the top collaborators of Andreas H. Scheel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas H. Scheel. Andreas H. Scheel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-score 2024 ·npj Precision Oncology ·(unknown), Andreas H. Scheel, Margaret Dugan, Robert Wild, (unknown), Barbara Holz, Johannes Brägelmann, Svenja Wagener‐Ryczek, Sabine Merkelbach‐Bruse, Juergen Wolf, Reinhard Büttner, (unknown), Matthias Scheffler, Axel M. Hillmer	0
2	Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer 2024 ·Archives of Pathology & Laboratory Medicine ·Josef Rüschoff, (unknown), (unknown), M. Elizabeth Hammond, Annette Lebeau, R. Yoshiyuki Osamura, Frédérique Penault‐Llorca, Federico Rojo, Chirag S. Desai, (unknown), Neil Atkey, (unknown), Andreas H. Scheel, Corrado D’Arrigo, Hans‐Ulrich Schildhaus, Giuseppe Viale, (unknown)	12
3	1329P FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC 2023 ·Annals of Oncology ·Lucia Nogová, Florian Malchers, Axel M. Hillmer, (unknown), (unknown), Sabine Merkelbach‐Bruse, Andreas H. Scheel, Janna Siemanowski, Matthias Scheffler, John Frank, (unknown), (unknown), Martin Wermke, Christian Grohé, Anna Kron, Niels Reinmuth, Frank Griesinger, Roman K. Thomas, Reinhard Büttner, Jennifer Moriatis Wolf	2
4	Tumour area infiltration and cell count in endoscopic biopsies of therapy-naive upper GI tract carcinomas by QuPath analysis: implications for predictive biomarker testing 2023 ·Scientific Reports ·Andreas H. Scheel, (unknown), Yuri Tolkach, Florian Gebauer, (unknown), Thomas Zander, Reinhard Buettner, Josef Rueschoff, Christiane J. Bruns, Wolfgang Schroeder, Alexander Quaas	1
5	1515 Gene edited iPSC-derived macrophages (iMACs) show increased phagocytosis in pre-clinical tumor models 2023 ·SHILAP Revista de lepidopterología ·(unknown), Michela Mirenda, (unknown), Philip Hublitz, (unknown), (unknown), (unknown), Garima Singh, (unknown), Tanja Schneider, Michael Epstein, (unknown), (unknown), (unknown), Michaël R. Paillasse, Andreas H. Scheel, (unknown), (unknown), (unknown)	0
6	1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort 2022 ·Annals of Oncology ·(unknown), Julie George, Andreas H. Scheel, Hans Anton Schloesser, Peter Brossart, (unknown), Frank Griesinger, (unknown), (unknown), Jens Panse, Martin Sebastian, Monika Serke, Rainer Wiewrodt, Sebastian Michels, Lucia Nogová, Richard Riedel, (unknown), (unknown), Roman K. Thomas, Jennifer Moriatis Wolf	1
7	Lymphangiosis carcinomatosa independently affects long-term survival of Non-Small Cell Lung Cancer patients 2021 ·Surgical Oncology ·Matthias Heldwein, Fabian Doerr, Georg Schlachtenberger, (unknown), Elmar Kuhn, Andreas H. Scheel, Maximilian Michel, Thorsten Wahlers, Khosro Hekmat	2
8	Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva 2019 ·Journal of Cancer Research and Clinical Oncology ·Fabinshy Thangarajah, Bernd Morgenstern, (unknown), Lars M. Schiffmann, Julian Puppe, Peter Mallmann, Stefanie Hamacher, Reinhard Buettner, Christina Alidousty, Barbara Holz, Andreas H. Scheel, Anne M. Schultheis	31
9	Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer 2016 ·Clinical Cancer Research ·Julie George, Motonobu Saito, Koji Tsuta, Reika Iwakawa, Kouya Shiraishi, Andreas H. Scheel, (unknown), Shun‐ichi Watanabe, Ryo Nishikawa, Masayuki Noguchi, Martin Peifer, Se Jin Jang, Iver Petersen, Reinhard Büttner, Curtis C. Harris, Jun Yokota, Roman K. Thomas, Takashi Kohno	93
10	Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie 2016 ·Der Pathologe ·Andreas H. Scheel, Manfred Dietel, Lukas C. Heukamp, Korinna Jöhrens, T. Kirchner, Simone Reu, Josef Rüschoff, Hans‐Ulrich Schildhaus, Peter Schirmacher, Markus Tiemann, Arne Warth, Wilko Weichert, Rieke Fischer, Julia Wolf, (unknown)	17
11	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas 2016 ·Modern Pathology ·Andreas H. Scheel, Manfred Dietel, Lukas C. Heukamp, Korinna Jöhrens, Thomas Kirchner, Simone Reu, Josef Rüschoff, Hans‐Ulrich Schildhaus, Peter Schirmacher, Markus Tiemann, Arne Warth, Wilko Weichert, Rieke Fischer, Jürgen Wolf, Reinhard Buettner	268
12	Comprehensive lymph node morphometry in rectal cancer using acetone compression 2015 ·Journal of Clinical Pathology ·Andreas H. Scheel, (unknown), Thilo Sprenger, (unknown), Julia Kitz, Β. Michael Ghadimi, Josef Rüschoff, Torsten Liersch, Peter Middel	10
13	Impact of updated HER2 testing guidelines in breast cancer—re-evaluation of HERA trial fluorescence in situ hybridization data 2015 ·Modern Pathology ·Oliver Stoß, Andreas H. Scheel, Iris Nagelmeier, Hans‐Ulrich Schildhaus, Thomas Henkel, Giuseppe Viale, Bharat Jasani, Michael Untch, Josef Rüschoff	42
14	Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy 2015 ·BMC Cancer ·Carina Heydt, (unknown), Jana Fassunke, Helen Künstlinger, Michaela A. Ihle, Andreas H. Scheel, Hans‐Ulrich Schildhaus, Florian Haller, Reinhard Büttner, Margarete Odenthal, Eva Wardelmann, Sabine Merkelbach‐Bruse	6
15	PD-L1 expression in small cell neuroendocrine carcinomas 2015 ·European Journal of Cancer ·Anne M. Schultheis, Andreas H. Scheel, Luka Ozretić, Julie George, Roman K. Thomas, Thorsten Hagemann, Thomas Zander, Jürgen Wolf, Reinhard Buettner	190
16	Cystic endosalpingiosis presenting as chronic back pain, a case report 2013 ·Diagnostic Pathology ·Andreas H. Scheel, (unknown), (unknown), Philipp Ströbel	8
17	Talcum induced pneumoconiosis following inhalation of adulterated marijuana, a case report 2012 ·Diagnostic Pathology ·Andreas H. Scheel, (unknown), (unknown), Inge Schmitz, Klaus Junker	26
18	Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies 2012 ·The Journal of Immunology ·Stefanie Derer, (unknown), Stefan Lohse, Andreas H. Scheel, Sven Berger, Christian Kellner, Matthias Peipp, Thomas Valerius	58
19	p73 is an essential regulator of neural stem cell maintenance in embryonal and adult CNS neurogenesis 2010 ·Cell Death and Differentiation ·Flaminia Talos, (unknown), Angelina V. Vaseva, (unknown), Stella E. Tsirka, Andreas H. Scheel, (unknown), Matthias Dobbelstein, Wolfgang Brück, Ute M. Moll	93
20	Ligand Binding to Transmembrane Receptors on Intact Cells or Membrane Vesicles Measured in a Homogeneous 1-Microliter Assay Format 2001 ·SLAS DISCOVERY ·Martin Klumpp, Andreas H. Scheel, (unknown), Michael P. Busch, Kenneth Murray, Andrew J. Pope	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact